China condemns US move to add Chinese medical equipment firms to Uyghur forced labour list

By Reuters News

- China's commerce ministry on Thursday condemned the United States for placing several Chinese companies on a list of businesses Washington alleges use Uyghur forced labour or source material from Xinjiang, and said Beijing would take steps to safeguard its interests.

The US added three Chinese medical equipment makers to the Uyghur Forced Labor Prevention Act Entity List, which includes entities that the US says use or facilitate the use of forced labour of Uyghurs and other minorities, or source material from the Xinjiang Uyghur Autonomous Region.

US Customs and Border Protection is instructed to stop goods from the listed companies from entering the United States unless exporters can ​rebut the presumption they were made with forced labour.

The list is contrary to the consensus reached by the two heads of state, and the US should immediately cease "political manipulation, smear campaigns, and unreasonable suppression of Chinese enterprises," the commerce ministry said.

The US added MGI Tech ‌Co Ltd 688114.SS, BGI Genomics Co Ltd 300676.SZ and Shenzhen BGI Technology Co Ltd, which the US says is also known as the BGI Group, to the list on Wednesday.

MGI Tech has rejected US allegations and said it had "zero tolerance" for forced labour. BGI Genomics and BGI Group, its parent, have also said they are not engaged in any form of forced labour.

A group of UN experts said in January there was "a persistent pattern" of alleged forced labour affecting Uyghur, Kazakh and Kyrgyz minority groups as well as Tibetans in Xinjiang and across multiple provinces of China. Beijing rejected the allegations as groundless.

In early 2025, China placed rival US medical equipment maker Illumina ILMN.O on its "unreliable entity" list.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.